Major cardiovascular events after COVID-19 in people with HIV


Por: Martin-Iguacel, R, Moreno-Fornes, S, Bruguera, A, Aceiton, J, Nomah, DK, Gonzalez-Cordon, A, Domingo, P, Curran, A, Imaz, A, Juanola, DD, Peraire, J, Borjabad, B, Fernandez, LA, Johansen, IS, Miro, JM, Casabona, J and Llibre, JM

Publicada: 1 may 2024 Ahead of Print: 1 abr 2024
Resumen:
Objectives: To assess the effect of COVID-19 on the postacute risk of cardiovascular events (CVEs) among people with HIV (PWH). Methods: Population-based matched cohort, including all PWH >= 16 years in the Catalan PISCIS HIV cohort. We estimated the incidence rate of the first CVE after COVID-19, analysed it a composite outcome (2020-2022). We adjusted for baseline differences using inverse probability weighting and used competing risk analysis. Results: We included 4199 PWH with and 14 004 PWH without COVID-19. The median follow-up was 243 days (interquartile range [IQR]: 93-455), 82% (14 941/18 203) were men, with a median age of 47 years. Overall, 211 PWH with COVID-19 and 621 without developed CVE, with an incidence rate of 70.2 and 56.8/1000 person-years, respectively. During COVID-19 infection, 7.6% (320/4199) required hospitalization and 0.6% (25/4199) intensive care unit admission, 97% (4079/4199) had CD4(+) T-cell >= 200 cells/mL, 90% (3791/4199) had HIV-RNA<50 copies/mL and 11.8% (496/4199) had previous CVE at baseline. The cumulative CVE incidence was higher among PWH after COVID-19 compared with PWH without COVID-19 during the first year (log-rank p=0.011). The multivariable analysis identified significantly increased CVE risk with age, heterosexual men, previous cardiovascular disease (CVD), and chronic kidney or liver disease. COVID-19 was associated with increased subsequent risk of CVE (adjusted hazard ratio 1.30 [95% CI, 1.09-1.55]), also when only including individuals without previous CVD (1.60 [95% CI, 1.11-2.29]) or nonhospitalized patients (1.34 [95% CI, 1.11-1.62]). Discussion: COVID-19 was associated with a 30% increased risk of major CVE in PWH during the subsequent year, suggesting that COVID-19 should be considered an additional CVD risk in PWH in the short term. (c) 2024 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.

Filiaciones:
Martin-Iguacel, R:
 Ctr Epidemiol Studies HIV AIDS, Dept Hlth, Badalona, Spain

 STI Catalonia CEEISCAT, Dept Hlth, Generalitat Catalunya, Badalona, Spain

 Odense Univ Hosp, Dept Infect Dis, Odense, Denmark

Moreno-Fornes, S:
 Ctr Epidemiol Studies HIV AIDS, Dept Hlth, Badalona, Spain

 STI Catalonia CEEISCAT, Dept Hlth, Generalitat Catalunya, Badalona, Spain

:
 Ctr Epidemiol Studies HIV AIDS, Dept Hlth, Badalona, Spain

 STI Catalonia CEEISCAT, Dept Hlth, Generalitat Catalunya, Badalona, Spain

 CIBER Epidemiol Salud Publ CIBERESP, Seville, Spain

 Univ Autonoma Barcelona, Dept Paediat Obstet & Gynecol & Prevent Med, Badalona, Spain

Aceiton, J:
 Ctr Epidemiol Studies HIV AIDS, Dept Hlth, Badalona, Spain

 STI Catalonia CEEISCAT, Dept Hlth, Generalitat Catalunya, Badalona, Spain

Nomah, DK:
 Ctr Epidemiol Studies HIV AIDS, Dept Hlth, Badalona, Spain

 STI Catalonia CEEISCAT, Dept Hlth, Generalitat Catalunya, Badalona, Spain

 Fdn Inst Dinvestigaci Ciencies Salut Germans & Tr, Badalona, Spain

Gonzalez-Cordon, A:
 Univ Barcelona, Hosp Clin Inst Invest Biomedi August Pi i Sunyer, Dept Infect Dis, Barcelona, Spain

Domingo, P:
 Hosp Univ Santa Creu & St Pau, Infect Dis Unit, Barcelona, Spain

Curran, A:
 Hosp Univ Vall dHebron, Dept Infect Dis, Barcelona, Spain

Imaz, A:
 Univ Barcelona, Hosp Univ Bellvitge Bellvitge Biomed Res Inst IDI, Dept Infect Dis, Lhospitalet De Llobregat, Spain

Juanola, DD:
 Hosp Univ Mutua Terrassa, Dept Internal Med, Barcelona, Spain

Peraire, J:
 Univ Rovira & Virgili, Hosp Univ Tarragona Joan XXIII, Dept Internal Med, IISPV, Tarragona, Spain

 Inst Salud Carlos III, CIBERINFEC, Madrid, Spain

Borjabad, B:
 Consorci Sanitari Integral, Dept Internal Med, Barcelona, Spain

Fernandez, LA:
 Hosp Mataro, Dept Internal Med, Mataro, Spain

Miro, JM:
 Univ Barcelona, Hosp Clin Inst Invest Biomedi August Pi i Sunyer, Dept Infect Dis, Barcelona, Spain

:
 Ctr Epidemiol Studies HIV AIDS, Dept Hlth, Badalona, Spain

 STI Catalonia CEEISCAT, Dept Hlth, Generalitat Catalunya, Badalona, Spain

 Univ Autonoma Barcelona, Dept Paediat Obstet & Gynecol & Prevent Med, Badalona, Spain

 Fdn Inst Dinvestigaci Ciencies Salut Germans & Tr, Badalona, Spain

:
 Univ Hosp Germans Trias & Pujol, Dept Infect Dis, Badalona, Spain

 Fight Infect Fdn, Badalona, Spain
ISSN: 1198743X





CLINICAL MICROBIOLOGY AND INFECTION
Editorial
Elsevier Limited, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 30 Número: 5
Páginas: 674-681
WOS Id: 001316676900001
ID de PubMed: 38342439

MÉTRICAS